Evidence map›Paper›PMID 36404209›Full record

ArticleTrends in immunology2022

Humans pIKK-up NLRP3 to skip NEK7.

R K Subbarao Malireddi, Thirumala-Devi Kanneganti

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

R K Subbarao MalireddiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Thirumala-Devi KannegantiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: Thirumala-Devi.Kanneganti@StJude.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NLRP3 inflammasome regulation is essential for controlling cell death and inflammation. Mechanistic studies in murine cells suggest a two-step model of priming and activation with an indispensable role for NEK7. However, in a recent article in Immunity, Schmacke et al. report that, in humans, transcription-independent NLRP3 activation occurs by circumventing NEK7 via IKKβ.

Indexed as

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsHumansMiceMice, Inbred C57BLNIMA-Related KinasesProtein Serine-Threonine KinasesInflammasomesNEK7 protein, humanNek7 protein, mouseNIMA-Related KinasesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseProtein Serine-Threonine Kinasescell deathIKKβinflammasomeNEK7NLRP3TAK1

Identifiers

PMID36404209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.